CN102824387A - Aralia taibaiensis saponin capsule, as well as preparation method and application thereof in preparation of antidiabetic medicines - Google Patents
Aralia taibaiensis saponin capsule, as well as preparation method and application thereof in preparation of antidiabetic medicines Download PDFInfo
- Publication number
- CN102824387A CN102824387A CN2012102781552A CN201210278155A CN102824387A CN 102824387 A CN102824387 A CN 102824387A CN 2012102781552 A CN2012102781552 A CN 2012102781552A CN 201210278155 A CN201210278155 A CN 201210278155A CN 102824387 A CN102824387 A CN 102824387A
- Authority
- CN
- China
- Prior art keywords
- mesh sieves
- capsule
- dry
- aaloside
- granulate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a preparation method of a medicine capsule taking aralia taibaiensis extracts as active pharmaceutical ingredients to treat diabetes. The preparation method comprises the following main processes of: uniformly mixing aralia taibaiensis extracts treated with a 100-mesh sieve with auxiliary materials, then preparing softwood with 70-90% ethanol as a wetting agent, treating the softwood with a 40-mesh sieve, drying wet granules in an oven at 50-60 DEG C for 5-7 hours, straightening the granules with the 40-mesh sieve and a 60-mesh sieve respectively and filling the obtained granules into a No.1 capsule, thus obtaining the medicine capsule. The preparation method has the following advantages and positive effects that aiming at the problems that as the traditional Chinese medicine extracts have strong moisture absorption, the traditional Chinese medicine extracts easily absorb moisture, have poor flowability and are hard to disintegrate in the capsule preparation process, the medicine capsule is obtained by investigating the prescription composition and the preparation processes, selecting the best auxiliary materials and adopting the optimum preparation processes; by adopting the preparation processes, the moisture absorption of aralia taibaiensis saponins is obviously reduced, the medicine is more stable and the curative effect is more reliable; and the processes are simple to operate, the repeatability is good, the production cycle is short, the auxiliary material cost is low and the solvents and energy are saved.
Description
Technical field
The invention belongs to the Chinese medicine preparation technical field, particularly a kind of Tai Bai Aaloside capsule and preparation technology thereof who treats the light or moderate type of deficiency of both QI and YIN type of person in middle and old age.
Background technology
Diabetes are one group, and to increase with glucose level in the chronic blood be the metabolic disease of characteristic, has the high distinguishing feature of sickness rate, disability rate and complication, and itself and cardiovascular disease and cancer also are called three healthy big illness of harm humans.The Western medicine blood sugar reducing function is outstanding, but certain limitation and untoward reaction are arranged, even serious toxic and side effects takes place, and like hypoglycemia, lactic acidosis, Liver and kidney toxicity etc., thereby the antidiabetic drug of searching high-efficiency low-toxicity is the target that medical expert pursues.Natural drug especially little, the action temperature of medicinal plants (Chinese herbal medicine) toxic and side effects and lasting, have the Comprehensive Treatment effect, can delay advantage such as complication.Therefore, take much count of both at home and abroad from Chinese herbal medicine excavating always and the exploitation blood sugar decreasing effect is good, untoward reaction is little, to the effective pharmaceutical preparation of complication.In addition, person in middle and old age's type of deficiency of both QI and YIN type 2 diabetes mellitus patient, its dizziness, symptom such as weak are comparatively obvious; It is improper to grasp like the antidiabetic drug consumption, or the Western medicine hypoglycemic activity is too quickly, causes blood glucose to descend suddenly; It is excessive to fluctuate, and tends to make dizziness, weak disease more obvious.Thereby this paradiabetes patient also urgently hopes to have and a kind ofly can delay the blood-sugar lowering tcm drug that blood sugar lowering can improve dizzy weak disease again.
Tai Bai Cortex araliae chinensis
(Aralia taibaiensis)Special product is in China Midwest Qin crust mountain area and surplus arteries and veins thereof.Tai Bai Cortex araliae chinensis total saponins has stronger inhibition lipid peroxidation, anti-glycosylation, suppresses the activity of AMS and promotion islets of langerhans β TC3 cell uelralante; Can significantly reduce the blood glucose of type 2 diabetes mellitus rat and can alleviate insulin resistant, improve the oxidative damage of body, result of the present invention shows that it is type 2 diabetes mellitus light, the moderate type of deficiency of both QI and YIN type 2 diabetes mellitus medicine of person in middle and old age particularly with potential using value.
Summary of the invention
The object of the present invention is to provide a kind of Tai Bai Aaloside capsule, to overcome the deficiency that Tai Bai Aaloside is prone to moisture absorption;
Another object of the present invention provides the capsular method for preparing of above-mentioned Tai Bai Aaloside;
A further object of the invention provides above-mentioned Tai Bai Aaloside capsule in the particularly application in the light or moderate type of deficiency of both QI and YIN type 2 diabetes mellitus medicine of person in middle and old age of preparation type 2 diabetes mellitus.
Implementation procedure of the present invention is following:
A kind of Tai Bai Aaloside capsule prepares through following method:
(1) extracts, extracts
Adopt weight 6 times of amounts, concentration of volume percent be 70% ethanol under 80 ℃ to the root bark fine powder extraction of Tai Bai Cortex araliae chinensis 3 times, each 1 h; After extracting solution simmer down to relative density 1.01, the water saturated n-butyl alcohol of reuse extracts 3 times with the volume ratio of 1:1; N-butanol layer is merged, concentrates De Taibai Cortex araliae chinensis extract extractum;
(2) dry, pulverizing
With Tai Bai Cortex araliae chinensis extract extract dry, pulverize dry extract, cross 100 mesh sieves, direct mistake 100 mesh sieves of adjuvant;
(3) mix, granulate
With dry extract and adjuvant mix homogeneously, use then concentration of volume percent as the ethanol of 70-90% as wetting agent system soft material, granulate with 40 mesh sieves at last, will be through next step operation of wet granular continuation of 40 mesh sieves;
(4) dry, granulate
With the wet grain drying that makes, must do granule, with 40 orders and 60 mesh sieves granulate respectively, will be through 40 mesh sieves not the granule through 60 mesh sieves be regarded as qualified;
(5) fill capsule
With above-mentioned qualified granule with No. 1 capsule fill, loading amount 0.25g/ grain.
In the above-mentioned steps (1), the quality percentage composition of Tai Bai Cortex araliae chinensis extract extractum Zhong Cortex araliae chinensis total saponins is 60-80%.
In the above-mentioned steps (2), extract extractum is put in the 40-60 ℃ of vacuum desiccator dry.
Said adjuvant is selected from starch, dextrin, lactose, microcrystalline Cellulose and carboxymethyl cellulose.
In the above-mentioned steps (3), the blended weight ratio of dry extract and adjuvant is 1:3-1:5.
In the above-mentioned steps (4), the baking temperature of wet granular is 50-60 ℃, and be 5-7 h drying time.
The capsular method for preparing of above-mentioned Tai Bai Aaloside may further comprise the steps:
(1) extracts, extracts
Adopt weight 6 times of amounts, concentration of volume percent be 70% ethanol under 80 ℃ to the root bark fine powder extraction of Tai Bai Cortex araliae chinensis 3 times, each 1 h; After extracting solution simmer down to relative density 1.01, the water saturated n-butyl alcohol of reuse extracts 3 times with the volume ratio of 1:1; The quality percentage composition that n-butanol layer is merged, concentrates the De Cortex araliae chinensis total saponins is the Tai Bai Cortex araliae chinensis extract extractum of 60-80%;
(2) dry, pulverizing
Tai Bai Cortex araliae chinensis extract extractum is put in the 40-60 ℃ of vacuum desiccator dry, pulverize dry extract, and cross 100 mesh sieves, direct mistake 100 mesh sieves of adjuvant, said adjuvant is selected from starch, dextrin, lactose, microcrystalline Cellulose and carboxymethyl cellulose;
(3) mix, granulate
With above-mentioned dry extract and adjuvant is the 1:3-1:5 mix homogeneously with the weight ratio, use then concentration of volume percent as the ethanol of 70-90% as wetting agent system soft material, granulate with 40 mesh sieves at last, will be through next step operation of wet granular continuation of 40 mesh sieves;
(4) dry, granulate
The wet granular that makes must be done granule at 50-60 ℃ of dry 5-7 h, with 40 orders and 60 mesh sieves granulate respectively, will be through 40 mesh sieves not the granule through 60 mesh sieves be regarded as qualified;
(5) fill capsule
With above-mentioned qualified granule with No. 1 capsule fill, loading amount 0.25g/ grain ， Han Aaloside 0.15-0.20 g.
Advantage of the present invention and good effect: it is strong to the present invention is directed to the Chinese medicine extract hygroscopicity; In glue capsule process, be prone to problems such as moisture absorption, mobile poor, difficult disintegrate,, select best adjuvant through investigating prescription composition and preparation technology; And adopt optimal preparation technology, thereby obtain the present invention.Preparation technology of the present invention obviously reduces Tai Bai Aaloside hygroscopicity, and medicine is more stable, and curative effect is more reliable; And technological operation is simple, and favorable reproducibility is with short production cycle, and cost of supplementary product is low, practices thrift the solvent and the energy.Tai Bai Aaloside capsule of the present invention meets the principle of traditional Chinese medical science treatment must aim at the pathogenesis of disease, and is both little to the human body side effect, little to the hepatic and renal function influence again; Hyperglycemia can be reduced, the hypoglycemia phenomenon can be avoided again.
The specific embodiment
Below in conjunction with specific embodiment the present invention is done further elaboration, but be not limited to this.
Embodiment 1:
The exsiccant Tai Bai of 100g Radix araliae chinensis (Cortex Araliae Chinensis) PIFEN is broken and cross 80 mesh sieves, obtain Tai Bai Cortex araliae chinensis medical material fine powder, reuse weight 6 times of amounts, mass percent concentrations are that 70% ethanol extracts backflow 3 times, each 1 h down at 80 ℃; After extracting liquid filtering, merging and simmer down to relative density 1.01; The water saturated n-butyl alcohol of reuse extracts 3 times with the volume ratio of 1:1; With the quality percentage composition of n-butanol layer filtration, merging and concentrated De Cortex araliae chinensis total saponins is the Tai Bai Cortex araliae chinensis extract extractum of 60-80%; Extractum is put in 50 ℃ of vacuum desiccators dry, pulverize dry extract.
Embodiment 2:
Took by weighing respectively 100 mesh sieves Aaloside extract dry extract 6.25g, cross starch 9.375g, the microcrystalline Cellulose 9.375g of 100 mesh sieves, progressively increase behind the method mix homogeneously with equivalent, use 75% ethanol to be wetting agent system soft material; Cross 40 mesh sieves; 50 ℃ of oven drying 6 h take out dried granule, 40 mesh sieve granulate; 60 mesh sieves sieve removes fine powder, the gained granule is inserted No. 1 capsule promptly get;
Embodiment 3:
Similar with embodiment 2, took by weighing 100 mesh sieve De Aaloside extract 6.25g, dextrin 18.75g, microcrystalline Cellulose 6.25g respectively, progressively increase behind the method mix homogeneously with equivalent; Use 80% ethanol to be wetting agent system soft material, cross 40 mesh sieves, 50 ℃ of oven drying 7 h; Take out dried granule; 40 mesh sieve granulate, 60 mesh sieves sieve removes fine powder, the gained granule is inserted No. 1 capsule promptly get.
Embodiment 4:
Similar with embodiment 2, Aaloside extract 6.25g, lactose 3.125g, the microcrystalline Cellulose 15.625g equivalent that took by weighing 100 mesh sieves is respectively progressively increased behind the mix homogeneously, uses 70% ethanol to be wetting agent system soft material; Cross 40 mesh sieves; 60 ℃ of oven drying 5 h take out dried granule, 40 mesh sieve granulate; 60 mesh sieves sieve removes fine powder, the gained granule is inserted No. 1 capsule promptly get.
Embodiment 5:
Similar with embodiment 2, Aaloside extract 6.25g, dextrin 12.5g, the carboxymethyl cellulose 12.5g equivalent that took by weighing 100 mesh sieves is respectively progressively increased behind the mix homogeneously, uses 85% ethanol to be wetting agent system soft material; Cross 40 mesh sieves; 55 ℃ of oven drying 6 h take out dried granule, 40 mesh sieve granulate; 60 mesh sieves sieve removes fine powder, the gained granule is inserted No. 1 capsule promptly get.
Embodiment 6:
Measure Tai Bai Aaloside grain forming qualification rate, hygroscopicity, flowability, the bulk density of embodiment 2-5 preparation:
(1) molding qualification rate
The grain forming qualification rate is the ratio that the granule of granularity between 40～60 orders accounts for total particle behind the granulate.The granule that obtains of invention is less than 50% between 40～60 orders, for mouldability general; More than 50%, be good moldability; Less than 20%, be insufficient formability.
(2) the percentile mensuration of moisture absorption
The glass exsiccator that the bottom is filled the supersaturation sodium chloride solution is put into 25 ℃ constant incubator 24 h, and the interior relative humidity of exsiccator this moment is 75%.Weighing botle is dried to constant weight, accurately weigh after the cooling, add the granule that invention makes respectively; Evenly spread out into 2 mm in the bottom thick, open bottle cap in 105 ℃ of about 5 h of baking to constant weight, after taking out capping plug and putting the exsiccator internal cooling; Accurately weigh; Again bottle cap is opened to be put in 25 ℃ of constant incubators and preserve, regularly weighing is calculated as follows the moisture absorption percentage rate.
(3) mensuration of angle of repose
Adopt the fixed funnel method: with 3 funnels series connection and be fixed in the height place of 1 cm on the graph paper of horizontal positioned; Next hopper outlet polishes; Carefully each sample is poured in the funnel of going up most, till the cone tip that forms touches nethermost bell mouth.Measure the diameter of conical base by graph paper, calculate angle of repose.Angle of repose, mobility of particle was good during less than 30 °, and flowability is bad during greater than 40 °.The angle of repose of directly filling during less than 40 °.
(4) mensuration of bulk density
Adopt the graduated cylinder method: get the granule that a certain amount of invention makes, the accurate title, decide, and puts in the 10 mL graduated cylinders, and hand-held graduated cylinder is vertically dropped on the plank by the height of 5 cm, after 5 vibrations, measures particulate volume repeatedly, is calculated as follows bulk density.
Measure the result: the made granule one-shot forming of embodiment 2-5 qualification rate is 75.13% ± 3.24%, and the moisture absorption percentage rate of 24h is 4.58% ± 0.84%, and be 28.4 ° ± 0.4 ° angle of repose, and bulk density is 0.5032 ± 0.0257 gmL
-1
Embodiment 7:
The capsular test of pesticide effectiveness of Tai Bai Aaloside that embodiment 3 makes:
(1) modeling, grouping and administration
With 40 body weight at the wistar of 220-240 g male rat lumbar injection nicotiamide 120 mg/kg, tail vein injection streptozotocin 65 mg/kg behind 15 min; In addition with 6 normal rats as contrast; Elder generation's intraperitoneal injection of saline, tail vein injection citrate buffer behind 15 min, respectively with these 46 rats with normal forage feed after 7 days; Overnight fasting; Tail vein blood is also measured fasting glucose (FBG) with blood glucose meter, and the eye socket blood sampling also detects serum insulin (FSI) with radio immunoassay, with ln (the calculating insulin sensitivity index (ISI) of 1/FBG * FSI).The standard of insulin resistant is: model group animal insulin Sensitivity Index and compared with normal have significant difference.With FBG greater than 7.0mmol/L and follow insulin resistant as experimental type 2 diabetes mellitus diagnostic criteria.Get 30 of the successful rats of modeling, be divided into 5 groups at random, 6 every group: (1) 1 model group, irritate stomach by the dosage of 2 mL/kg and give normal saline, once a day, continuous 4 weeks.(2) 3 treatment groups are irritated stomach by the dosage of 80,160,320 mg/kg respectively and are given embodiment 3 and make De Aaloside capsule, once a day, and continuous 4 weeks.(3) 1 positive drug groups are irritated stomach by the dosage of 76.5 mg/kg and are given metformin, once a day, and continuous 4 weeks.Simultaneously, 6 rats of not modeling as the normal control group, are irritated stomach by the dosage of 2 mL/kg and give normal saline, once a day, continuous 4 weeks.Measure body weight after the administration week about one time, and calculate average food ration.
(2) collection of BIAO and BEN and processing
During last day, 1% pentobarbital sodium anesthetized rat, (1) tail vein are got blood and are surveyed blood glucose in administration.(2) abdominal aortic blood and separation of serum are surveyed serum levels of triglyceride (TG), serum cholesterol (TC), serum high-density LP cholesterol (HDL-C), serum low-density LP cholesterol (LDL-C), serum insulin.(3) get pancreas and place 10% formalin solution fixing, routine paraffin wax embedding, section, with HE dyeing, mirror is estimated the pathological changes situation down.
(3) body weight, food ration
Observe the body weight and the situation of ingesting of every administration one all rats continuously, the result sees table 1 and table 2 respectively.
It is thus clear that; Prolongation along with the administration natural law; The relative normal group of the body weight of model group rat significantly reduces, average food ration significantly increases, but Gei is Yu behind Aaloside capsule and the metformin, rat body weight has in various degree increase and food ration obviously to reduce; And along with the increase of dosage, the weight increase amplitude increases thereupon, average food ration moves closer to normal group.
(4) blood glucose and insulin
With Di Ji Liang Aaloside capsule for treating type 2 diabetes mellitus rat, blood glucose and the change of insulin compare with model group there was no significant difference (
P>0.05); With the experimental type 2 diabetes mellitus rat of middle and high Ji Liang Aaloside capsule for treating, though blood glucose is not reduced to normal level, insulin does not rise to normal level yet, compare with model group significant difference is all arranged (
P<0.05); With metformin treatment type 2 diabetes mellitus rat, blood glucose and insulin also have significance to improve, and the result sees table 3.
（5）TG、TC、HDL-C、LDL-C
With Di Ji Liang Aaloside capsule for treating type 2 diabetes mellitus rat, TC, TG, LDL-C descend to some extent, and HDL-C rises to some extent, but compare with model group still there was no significant difference (
P>0.05); With in Ji Liang Aaloside capsule for treating type 2 diabetes mellitus rat, except HDL-C and LDL-C, TC and TG compare with model group all have significance improve (
P<0.05); With Gao Ji Liang Aaloside capsule or metformin treatment type 2 diabetes mellitus rat, all indexs are compared with model group all has significant difference (
P<0.05), and basically near the normal group level.The result sees table 4.
(6) pancreatic tissue pathology
The pancreas of model group islets of langerhans telangiectasis, hyperemia, islet cells have occurred and has counted pathological changes clearly such as minimizing.Give with Gao Ji Liang Aaloside capsule or positive drug after rat pancreas have the islets of langerhans structure of similar normal group, islets of langerhans and acinar tissue boundary clear on every side can only be observed discrete acute and chronic inflammatory cell; In, low dose group can observe more acute and chronic inflammatory cell, islets of langerhans number and compared with normal reduce to some extent.
， Aaloside capsule can significantly improve body weight, food ration, blood glucose, the serum biochemistry index level of experimental type 2 diabetes mellitus rat in sum, and can improve the diabetes rat serum insulin levels to a certain extent.After the morphology experiment shows to Yu Aaloside capsule; The trend Biao Ming Aaloside capsule that recovers is arranged progressively is effective potential drug of anti-type 2 diabetes mellitus to the pancreas of diabetes rat under the light microscopic, the medicine of the light or moderate type of deficiency of both QI and YIN type 2 diabetes mellitus of particularly anti-person in middle and old age.
Claims (10)
1. too white Aaloside capsule is characterized in that through following method preparation:
(1) extracts, extracts
Adopt weight 6 times of amounts, concentration of volume percent be 70% ethanol under 80 ℃ to the root bark fine powder extraction of Tai Bai Cortex araliae chinensis 3 times, each 1 h; After extracting solution simmer down to relative density 1.01, the water saturated n-butyl alcohol of reuse extracts 3 times with the volume ratio of 1:1; N-butanol layer is merged, concentrates De Taibai Cortex araliae chinensis extract extractum;
(2) dry, pulverizing
With Tai Bai Cortex araliae chinensis extract extract dry, pulverize dry extract, cross 100 mesh sieves, direct mistake 100 mesh sieves of adjuvant;
(3) mix, granulate
With dry extract and adjuvant mix homogeneously, use then concentration of volume percent as the ethanol of 70-90% as wetting agent system soft material, granulate with 40 mesh sieves at last, will be through next step operation of wet granular continuation of 40 mesh sieves;
(4) dry, granulate
With the wet grain drying that makes, must do granule, with 40 orders and 60 mesh sieves granulate respectively, will be through 40 mesh sieves not the granule through 60 mesh sieves be regarded as qualified;
(5) fill capsule
With above-mentioned qualified granule with No. 1 capsule fill, loading amount 0.25g/ grain.
2. Tai Bai Aaloside capsule according to claim 1 is characterized in that: in the step (1), the quality percentage composition of Tai Bai Cortex araliae chinensis extract extractum Zhong Cortex araliae chinensis total saponins is 60-80%.
3. Tai Bai Aaloside capsule according to claim 1 is characterized in that: in the step (2), extract extractum is put in the 40-60 ℃ of vacuum desiccator dry.
4. Tai Bai Aaloside capsule according to claim 1, it is characterized in that: said adjuvant is selected from starch, dextrin, lactose, microcrystalline Cellulose and carboxymethyl cellulose.
5. Tai Bai Aaloside capsule according to claim 1 is characterized in that: in the step (3), the blended weight ratio of dry extract and adjuvant is 1:3-1:5.
6. Tai Bai Aaloside capsule according to claim 1 is characterized in that: in the step (4), the baking temperature of wet granular is 50-60 ℃, and be 5-7 h drying time.
7. the capsular method for preparing of the described Tai Bai of claim 1 Aaloside may further comprise the steps:
(1) extracts, extracts
Adopt weight 6 times of amounts, concentration of volume percent be 70% ethanol under 80 ℃ to the root bark fine powder extraction of Tai Bai Cortex araliae chinensis 3 times, each 1 h; After extracting solution simmer down to relative density 1.01, the water saturated n-butyl alcohol of reuse extracts 3 times with the volume ratio of 1:1; N-butanol layer is merged, concentrates De Taibai Cortex araliae chinensis extract extractum;
(2) dry, pulverizing
With Tai Bai Cortex araliae chinensis extract extract dry, pulverize dry extract, and cross 100 mesh sieves, direct mistake 100 mesh sieves of adjuvant;
(3) mix, granulate
With dry extract and adjuvant mix homogeneously, use then concentration of volume percent as the ethanol of 70-90% as wetting agent system soft material, granulate with 40 mesh sieves at last, will be through next step operation of wet granular continuation of 40 mesh sieves;
(4) dry, granulate
With the wet grain drying that makes, must do granule, with 40 orders and 60 mesh sieves granulate respectively, will be through 40 mesh sieves not the granule through 60 mesh sieves be regarded as qualified;
(5) fill capsule
With above-mentioned qualified granule with No. 1 capsule fill, loading amount 0.25g/ grain.
8. the capsular method for preparing of Tai Bai Aaloside according to claim 7 may further comprise the steps:
(1) extracts, extracts
Adopt weight 6 times of amounts, concentration of volume percent be 70% ethanol under 80 ℃ to the root bark fine powder extraction of Tai Bai Cortex araliae chinensis 3 times, each 1 h; After extracting solution simmer down to relative density 1.01, the water saturated n-butyl alcohol of reuse extracts 3 times with the volume ratio of 1:1; The quality percentage composition that n-butanol layer is merged, concentrates the De Cortex araliae chinensis total saponins is the Tai Bai Cortex araliae chinensis extract extractum of 60-80%;
(2) dry, pulverizing
Tai Bai Cortex araliae chinensis extract extractum is put in the 40-60 ℃ of vacuum desiccator dry, pulverize dry extract, and cross 100 mesh sieves, direct mistake 100 mesh sieves of adjuvant, said adjuvant is selected from starch, dextrin, lactose, microcrystalline Cellulose and carboxymethyl cellulose;
(3) mix, granulate
With above-mentioned dry extract and adjuvant is the 1:3-1:5 mix homogeneously with the weight ratio, use then concentration of volume percent as the ethanol of 70-90% as wetting agent system soft material, granulate with 40 mesh sieves at last, will be through next step operation of wet granular continuation of 40 mesh sieves;
(4) dry, granulate
The wet granular that makes must be done granule at 50-60 ℃ of dry 5-7 h, with 40 orders and 60 mesh sieves granulate respectively, will be through 40 mesh sieves not the granule through 60 mesh sieves be regarded as qualified;
(5) fill capsule
With above-mentioned qualified granule with No. 1 capsule fill, loading amount 0.25g/ grain.
9. the application of the described Tai Bai of claim 1 Aaloside capsule in preparation type 2 diabetes mellitus medicine.
10. the described Tai Bai of claim 1 Aaloside capsule application in the light or moderate type of deficiency of both QI and YIN type 2 diabetes mellitus medicine the preparation person in middle and old age.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012102781552A CN102824387A (en) | 2012-08-07 | 2012-08-07 | Aralia taibaiensis saponin capsule, as well as preparation method and application thereof in preparation of antidiabetic medicines |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012102781552A CN102824387A (en) | 2012-08-07 | 2012-08-07 | Aralia taibaiensis saponin capsule, as well as preparation method and application thereof in preparation of antidiabetic medicines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102824387A true CN102824387A (en) | 2012-12-19 |
Family
ID=47327833
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012102781552A Pending CN102824387A (en) | 2012-08-07 | 2012-08-07 | Aralia taibaiensis saponin capsule, as well as preparation method and application thereof in preparation of antidiabetic medicines |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102824387A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102813688A (en) * | 2012-08-14 | 2012-12-12 | 中国人民解放军第四军医大学 | Anti-insulin resistance adenosine monophosphate-activated protein kinase agonist |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102579530A (en) * | 2012-02-24 | 2012-07-18 | 中国人民解放军第四军医大学 | Preparation method of aralia taibaiensis total saponin having diabetes mellitus resisting effect and medicament |
-
2012
- 2012-08-07 CN CN2012102781552A patent/CN102824387A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102579530A (en) * | 2012-02-24 | 2012-07-18 | 中国人民解放军第四军医大学 | Preparation method of aralia taibaiensis total saponin having diabetes mellitus resisting effect and medicament |
Non-Patent Citations (2)
| Title |
|---|
| 《中国博士学位论文全文数据库》 20090104 奚苗苗 中药皂苷的抗糖尿病活性筛选和药效学研究 第27、45、46、48、75页 9、10 , * |
| 奚苗苗: "中药皂苷的抗糖尿病活性筛选和药效学研究 ", 《中国博士学位论文全文数据库》, 4 January 2009 (2009-01-04) * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102813688A (en) * | 2012-08-14 | 2012-12-12 | 中国人民解放军第四军医大学 | Anti-insulin resistance adenosine monophosphate-activated protein kinase agonist |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1899361A (en) | Zhenqi medicinal composition and its preparation | |
| CN102552388B (en) | Cyclocarya paliurus capsule and preparation method thereof | |
| CN102525945A (en) | Preparation method for cyclocarya paliurus(Batal)Ijinskaja hypoglycemic granules | |
| CN103285070A (en) | Preparation method and application of chickpea sprout extract dispersible tablet | |
| JP2016539173A (en) | Oral solid preparations containing broad-kind grasses and total flavonoids, and uses thereof | |
| CN101884749B (en) | Particle for eliminating turbidity and treating arthralgia | |
| CN101167863A (en) | Proprietary Chinese medicine for treating diabetes and nephrosis and preparing method thereof | |
| CN101036707A (en) | Pill for easing heart and the method for preparing the same | |
| CN102085257A (en) | Preparation method of micro-pills prepared from cassia twig and tuckahoe | |
| CN102302615B (en) | Effective site group of daphne giraldii nitsche leaf, preparation method, medicinal composition and application thereof | |
| CN113730464A (en) | New application of rhizoma coptidis pill, extract and pharmaceutical composition thereof and rhizoma coptidis pill product | |
| CN111494360A (en) | Application of epimedin C in medicine for treating diabetic liver injury | |
| CN102824387A (en) | Aralia taibaiensis saponin capsule, as well as preparation method and application thereof in preparation of antidiabetic medicines | |
| CN102579530A (en) | Preparation method of aralia taibaiensis total saponin having diabetes mellitus resisting effect and medicament | |
| CN101455778B (en) | Traditional Chinese medicine preparation capable of reducing fever and relieving sore-throat and preparation method thereof | |
| CN107811991B (en) | Preparation method of enteric preparation containing morinda officinalis fructo-oligosaccharide and preparation obtained by preparation method | |
| CN100500195C (en) | Medicinal Smilax indica micro pill and its preparing method | |
| CN102526237A (en) | Medicinal composition for removing advanced oxidation protein final product and application thereof | |
| CN102441064A (en) | Traditional Chinese medicine composition for treating diabetes and preparation thereof | |
| CN1772234A (en) | Chinese medicine prepn for treating women's disease and its prepn | |
| CN105030806B (en) | A kind of medical composition and its use for treating diabetes | |
| CN1311852C (en) | Yuquan extractum and its medicine composition and use | |
| CN1311853C (en) | Quick release Yuquan micropill | |
| CN1840075A (en) | Diabetes-treating capsule and preparation method thereof | |
| CN104056020B (en) | A kind of Chinese medicine composition for treating metabolic syndrome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20121219 |